ZAI LAB (09688) News

These Analysts Think Zai Lab Limited's (NASDAQ:ZLAB) Earnings Are Under Threat

Simply Wall StNov 12 20:37

The anticipated flu epidemic has spurred a significant rise in biopharmaceutical stocks, with industry giant BeiGene leading the rally. Institutions express optimism about the trend of innovative drug exports.

①Why is BeiGene trending strongly? ②How do institutions view the future overseas expansion trends and development prospects of China's innovative pharmaceutical companies?

cls.cnNov 12 14:30

Express News | Hong Kong-listed innovative drug concept stocks rebounded collectively, with BeiGene and Ascletis Pharma rising nearly 5%, Jinxin Fertility surging over 4%, and Akeso Inc. gaining close to 4%.

BreakingsNov 12 09:48

Zai Lab Ltd Announces Share Options and Restricted Share Units Grants

TipRanksNov 11 17:38

Zai Lab (09688.HK): Grant of options to subscribe for a total of 500 American Depositary Shares and restricted share units covering 72,100 American Depositary Shares.

Gelonghui, November 11th丨Zai Lab (09688.HK) announced that on November 10, 2025 (Eastern Time), the company granted stock options to one grantee for the purchase of a total of 500 American Depositary Shares under the 2024 Equity Incentive Plan and awarded restricted share units involving a total of 72,100 American Depositary Shares to 78 grantees.

Gelonghui FinanceNov 11 17:14

Zai Lab Ltd (1ZLB) Gets a Buy From UBS

TipRanksNov 11 08:35 · Ratings

Bank of America Securities has lowered its target price for Zai Lab (09688.HK) to HKD 19.92, citing sales pressure on its core products.

According to a research report by BofA Securities, Zai Lab's (09688.HK) total revenue in the third quarter increased by 13% year-on-year to US$116 million, with product revenue growing by 13% year-on-year to US$115 million. Among this, revenues from VYVGART and VYVGART Hytrulo increased by 2% year-on-year, ZEJULA decreased by 12%, and NUZYRA increased by 54%. The net loss narrowed by 14% year-on-year to US$36 million. The company has revised its full-year revenue guidance for 2023 downward from the previous range of US$560 million to US$590 million to US$460 million. The bank has adjusted its revenue forecasts for 2025 to 2027 accordingly.

AASTOCKSNov 10 11:12

Top Gainers in Hong Kong Stocks This Week | Weichai Power surged nearly 27% during the week after securing a license agreement for the manufacture of solid oxide fuel cells; Ascletis Pharma rose over 20%, with its NLRP3 inhibitor fetching a US$881.5 milli

This week, the Hang Seng Index rose by a cumulative 1.29% to close at 26,241.83 points. During the same period, the Hang Seng Tech Index fell by a cumulative 1.2% to close at 5,837.36 points, while the H-share Index gained a cumulative 1.08% to close at 9,267.56 points.

Futu NewsNov 8 11:21

Zai Lab Ltd's Earnings Call: Mixed Outlook Amid Growth and Challenges

TipRanksNov 8 08:57

What Does The Future Hold For Zai Lab Limited (NASDAQ:ZLAB)? These Analysts Have Been Cutting Their Estimates

Yahoo FinanceNov 8 02:58

BofA Securities Maintains Zai Lab(ZLAB.US) With Hold Rating, Cuts Target Price to $25.7

Futu NewsNov 7 20:34 · Ratings

Hong Kong Stock Market Review: Indices remained sluggish throughout the day! The Hang Seng Tech Index fell by 1.8%, while the gold sector bucked the trend with gains.

On November 7, the three major indexes of Hong Kong stocks opened lower and remained weak throughout the day. By the close, the Hang Seng Index fell by 0.92% to 26,241 points, the H-share Index dropped by 0.94% to 9,267 points, and the Hang Seng Tech Index declined by 1.8% to 5,837 points. On the sector front, large technology stocks generally performed poorly, with semiconductor and chip stocks, automobile stocks, and other popular sectors mostly falling, while education stocks and wind power stocks also trended lower. On the other hand, a turning point signal emerged in the polysilicon industry, driving a significant rise in the new energy materials sector. Flat Glass Group surged 9% against the market trend, while Xinyi Solar and GCL Technology both showed strong performances. Gold stocks continued to lead gains among non-ferrous metal stocks, followed by building materials.

Gelonghui FinanceNov 7 16:38

Zai Lab (09688.HK) Q3 Performance: Steady Growth in Sales of Key Product Efgartigimod; Continued Narrowing of Losses

Net product revenue in the third quarter was US$115 million (up 13% year-over-year and 6% quarter-over-quarter). R&D expenses were US$47.9 million (-27%), and SG&A expenses were US$70.1 million (+4%). Adjusted operating loss...

Haitong InternationalNov 7 14:52

UBS Group: Zai Lab (09688.HK) reports weaker-than-expected Q3 results, downgrades full-year revenue guidance.

UBS Group issued a research report stating that Zai Lab (09688.HK) recorded total revenue of US$116 million in the third quarter according to U.S. Generally Accepted Accounting Principles (GAAP), representing a 14% year-over-year increase but falling below market expectations. The net loss narrowed year-over-year to US$36 million, yet still underperformed the market's forecasted net loss of US$29.2 million. The report noted that Zai Lab has lowered its full-year revenue guidance for this year, revising it downward from the previous range of US$560 million to US$590 million to at least US$460 million. Nevertheless, management remains confident in long-term revenue growth driven by its pipeline in China and globally. UBS Group maintains a 'Buy' rating for the company with a target price of HK$33.

AASTOCKSNov 7 11:48

Zai Lab (09688.HK) plunged 8% to a more than one-year low after its quarterly results fell short of expectations.

Zai Lab (09688.HK) dropped 8.4% in early trading today (7th), hitting HKD 17.86, the lowest level since October last year. The trading volume reached 13.064 million shares, with a turnover of HKD 235 million. The company announced its Q3 financial results as of September under U.S. Generally Accepted Accounting Principles (GAAP), reporting total revenue of USD 116 million, an increase of 14% year-on-year. The net loss narrowed from USD 41.67 million in the same period last year to USD 35.96 million, or a loss per share of 3 U.S. cents. The company revised its full-year revenue guidance to at least USD 460 million. UBS Group noted that Zai Lab's Q3 results fell short of expectations, with revenue 18% below market forecasts.

AASTOCKSNov 7 10:26

Zai Lab's Q3 Loss Narrows as Revenue Jumps 14%; Shares Fall 8%

MT NewswiresNov 7 10:11

Zai Lab (9688.HK) Quarterly Report Commentary: Focus on the International R&D Progress of Core Pipeline ZOCI

The company’s 3Q25 performance fell below expectations. In the near term, it is recommended to focus on the R&D progress of the core pipeline asset Zoci, with multiple data readouts expected in 1H26 that could drive a positive share price reaction. 3Q25 revenue was significantly lower than expected, with a net loss.

SPDB InternationalNov 7 00:00

Zai Lab (09688.HK) Narrows Q3 Loss to US$35.96 Million

Zai Lab (09688.HK) (ZLAB.US) announced its financial results for the third quarter ended September, prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Total revenue reached $116 million, representing a 14% increase year-over-year. Net product revenue amounted to $115 million, growing by 13%, primarily driven by increased sales of NUZYRA and KIT-001. Benefiting from higher product revenue and reduced operating expenses, the company’s net loss narrowed to $35.96 million from $41.67 million in the same period last year, with a loss per share of $0.03. For the fiscal year 2025, the company adjusted its full-year total revenue guidance to at least $460 million.

AASTOCKSNov 6 23:30

H-share Announcements | Galaxy Entertainment Group's Q3 net revenue reached HKD 12.2 billion, up 14% year-on-year.

China Tobacco Hong Kong has signed an exclusive global distribution agreement for the 'Crown' cigar with Anhui China Tobacco.

Zhitong FinanceNov 6 22:57

Zai Lab Reports Strong Q3 2025 Results and Pipeline Progress

TipRanksNov 6 22:40